Goodwin Procter advised Scholar Rock Holding Corporation on the deal. Scholar Rock Holding Corporation announced the completion of its registered direct offering of 16,326,530 shares of common...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised HIBio on the deal while Orrick represented MorphoSys. HIBio announced its equity participation agreement and license agreements with MorphoSys AG (FSE: MOR; NASDAQ: MOR)....
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Flagship Pioneering on the deal. Flagship Pioneering announced its collaboration agreement with Novo Nordisk A/S to create a portfolio of novel research programs...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised MOMA Therapeutics on the deal. MOMA Therapeutics announced its completion of a $150 million Series B Financing. MOMA Therapeutics is a biopharmaceutical company...
You must be a Standard 1 Year member to access this content.
Goodwin advised Nuvig Therapeutics on the deal. Nuvig Therapeutics announced its $47 million Series A financing and the launch of the company to develop novel therapeutics that...
You must be a Standard 1 Year member to access this content.
Goodwin advised LifeMine Therapeutics on the deal. LifeMine Therapeutics announced its completion of a $175 million Series C financing. LifeMine Therapeutics is reinventing drug discovery by mining...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Arrakis Therapeutics on the deal. Arrakis Therapeutics announced its research collaboration agreement with Amgen (NASDAQ:AMGN), focused on the discovery and development of RNA degrader...
You must be a Standard 1 Year member to access this content.
Goodwin advised Korro Bio on the deal. Korro Bio, Inc. announced its $116 million Series B financing. Korro is an RNA editing company focused on discovery...
You must be a Standard 1 Year member to access this content.
Goodwin advised Generate Biomedicine on the deal. Generate Biomedicines announced its research collaboration agreement with Amgen (NASDAQ: AMGN) to discover and create protein therapeutics for five clinical...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised EQRx on the deal while White & Case LLP advised CM Life Sciences III Inc. EQRx, Inc. announced its definitive merger agreement with CM...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Vida Ventures on the deal while Goodwin Procter represented Vigil Neuroscience. Vigil Neuroscience, a biotechnology company harnessing the power of...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Absci, while Latham & Watkins represented the underwriters in the offering. Absci Corporation (Absci), the synthetic biology company unlocking the potential of proteins...
You must be a Standard 1 Year member to access this content.
